Covidien Announces FDA 510(k) Clearance of the Nellcor™ Bedside SpO2 Patient Monitoring System
Covidien (NYSE: COV) today announced the U.S. Food and Drug Administration (FDA) has granted the Company 510(k) clearance to market the Covidien Nellcor™ Bedside SpO2 Patient Monitoring System. The new patient monitoring system is now available for sale in the U.S.
The Nellcor Bedside SpO2 system with OxiMax™ technology continuously monitors SpO2 and pulse rate for adult, pediatric and neonatal patients, giving clinicians instant access to comprehensive trending respiratory information. This enables clinicians to detect subtle, yet critical, heart rate and SpO2 variations earlier and thus address respiratory complications sooner.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.